CoreLine Soft's Aorta Analysis AI Wins US FDA Approval, Its 13th Achievement
Predicted impact: Medium
New US FDA approval for aorta analysis AI; small company, regulatory milestone, no sales size given
Coreline Soft코어라인소프트
384470 · KOSDAQ · ₩384470 · 코어라인소프트
₩2,240▼ ₩95 (4.07%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −46.60%
- Market cap
- ₩40B
- Enterprise value
- ₩42B
- P/E
- —
- P/B
- 3.1×
- Dividend yield
- 0.0%
- ROE
- −107.2%
- Net margin
- −267.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−52.2% from the high
₩1,820Today: ₩2,215 – ₩2,335₩4,690
Returns
- 1W−6.1%
- 1M−12.7%
- 3M−18.5%
- 6M−41.7%
- YTD−45.1%
- 1Y−46.6%
- Volume today
- 82,865
- 1.2× the 20-day average
- Traded today
- ₩185M
- Listed shares
- 17,946,333
- EPS (12 months)
- −₩774
- Earnings yield −34.5%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
- MomentumWeak-12.2% over the last month; the price is below its 20-day average.
- News impactSome1 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Coreline Soft stock overview
Coreline Soft (코어라인소프트, KRX: 384470) is listed on KOSDAQ, in the Software sector. The company, founded in 2012, is an artificial intelligence medical imaging software developer that makes and sells medical device products to help doctors diagnose disease through fully automated quantitative analysis of medical images, mainly CT scans of the chest. Its shares closed at ₩2,240 on Oct 27, 2026, down 4.07% on the day, giving it a market value of ₩40B.
Key facts
- Market cap
- ₩40B
- Sector
- Software
- Latest price change
- −4.07%
- As of
- Oct 27, 2026
- Main business
- The company, founded in 2012, is an artificial intelligence medical imaging software developer that makes and sells medical device products to help doctors diagnose disease through fully automated quantitative analysis of medical images, mainly CT scans of the chest.
Quick answers about Coreline Soft
- What does Coreline Soft do?
- The company, founded in 2012, is an artificial intelligence medical imaging software developer that makes and sells medical device products to help doctors diagnose disease through fully automated quantitative analysis of medical images, mainly CT scans of the chest. Its main products, including AVIEW LCS, AVIEW COPD and AVIEW CAC, target lung cancer, chronic obstructive pulmonary disease and coronary artery calcification, and its customers are hospitals and the medical staff who use them. It sells directly, through large medical device makers, through AI platform companies and through government and research projects, with operations in Korea, Europe and North America.
- What is the market cap of Coreline Soft?
- The market capitalisation of Coreline Soft was ₩40B at the close on Oct 27, 2026.
- Who are the largest shareholders of Coreline Soft?
- According to the latest official filings, the largest reported holders are Kim Jin-guk (20.13%, as of Sep 23, 2026); Lee Jae-yeon (6.55%, as of Jun 17, 2025); National Pension Service (0.84%, as of Dec 31, 2023).
- When is the next earnings report from Coreline Soft?
- Korean companies rarely announce results dates in advance. Based on when Coreline Soft filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Coreline Soft?
- Yes. The National Pension Service held 0.84% of Coreline Soft shares as of Dec 31, 2023.
Company profile
The company, founded in 2012, is an artificial intelligence medical imaging software developer that makes and sells medical device products to help doctors diagnose disease through fully automated quantitative analysis of medical images, mainly CT scans of the chest. Its main products, including AVIEW LCS, AVIEW COPD and AVIEW CAC, target lung cancer, chronic obstructive pulmonary disease and coronary artery calcification, and its customers are hospitals and the medical staff who use them. It sells directly, through large medical device makers, through AI platform companies and through government and research projects, with operations in Korea, Europe and North America.
Written by AI from the company's latest annual report.
- Korean name
- 코어라인소프트
- Sector
- Software
- Themes
- AI healthcare
- CEO
- 김진국
- Founded
- Sep 2012
- Listed
- Sep 2023
- Listed shares
- 17,946,333
- Fiscal year ends
- Month 12
- Website
- www.corelinesoft.com
Similar companies
- Hyundai Autoever307950 · ₩8.9T₩325,500+4.16%
- Krafton259960 · ₩8.4T₩182,500−0.54%
- NC036570 · ₩4.3T₩198,700−1.39%
- Netmarble251270 · ₩2.8T₩33,650+0.30%
- PearlAbyss263750 · ₩2.1T₩34,050−0.87%
- Shift UP462870 · ₩1.7T₩29,550+0.34%
- NHN181710 · ₩1.6T₩49,850+1.53%
- Kakao Games293490 · ₩1.3T₩11,850+5.80%
Recent news
Recent filings
See all- Investor relations (IR) eventOct 13, 2026
- Earnings Outlook on Consolidated Financial Statements (Fair Disclosure)Oct 13, 2026
- 5%+ holding reportSep 23, 2026
- Insider shareholding reportSep 23, 2026
- [Amended] Notice of Stock Purchase Option GrantSep 23, 2026
Titles in Korean until English translations are added.
Also known as: Coreline Soft / 코어라인소프트 / 384470 / KRX:384470
Source: KRX statistical information